INTRODUCTION
Renal cell carcinoma (RCC) is the most common of the kidney cancers, accounting for 90-95% of neoplasms of the kidney. It is the third most common genitourinary cancer, behind prostate and bladder cancer, and accounts for around 3% of all human malignancies. 1, 2 The most common of the RCCs, at approximately 85%, is clear cell RCC (ccRCC). [1] [2] [3] RCCs are traditionally thought to arise from the epithelial cells of the renal tubule, most commonly the proximal tubular epithelium, especially for ccRCC. 3, 4 Patients usually have no symptoms during early phases of renal cancer growth and, in many cases, the diagnosis of RCC is made incidentally while scanning the kidneys for other diseases, or made late with patients presenting with RCC metastases. The average survival following metastatic RCC is about 4 months, and only 10% of patients survive 1 year. 5 Thus, the identification of effective therapeutic biomarkers for early diagnosis and for disease progression is imperative. This requires identification of tissue-specific molecules that are implicated in the development and progression of RCC.
Although there is now evidence for a significant role for the tumour necrosis factor (TNF) receptor-associated factor (TRAF) family of proteins in the pathogenesis of some cancers like lymphomas and myelomas, [6] [7] [8] [9] [10] [11] little is known about their role in the development and progression of RCC. The TRAF family consists of six members (TRAF-1 to TRAF-6) that have a conserved C-terminal domain required for binding signaltransduction adaptor proteins to the TNF receptor. [12] [13] [14] Two additional functional domains located at the N terminus, the zinc finger and the RING finger domains, may be essential for the activation of specific downstream signalling components and transcription factors, such as nuclear factor kappaB (NFkB).
11,13
TRAF-1 is an adaptor protein that is involved in the regulation of cell survival, proliferation, differentiation and stress responses. 11, 12, 15 Recent published data from our laboratory demonstrated that RCC cells, treated in vitro with an immunotherapy (interferon-gamma) with and without radiation to induce apoptosis, had significantly increased expression of TRAF-1 RNA and protein concurrent with increased apoptosis. 16 Use of silencing RNA to TRAF-1 in RCC cell culture experiments decreased therapy-induced apoptosis. In a later publication on TRAF-1 expression in human RCC and normal kidney samples at Princess Alexandra Hospital in Brisbane, Australia, high TRAF-1 was found in the proximal tubular epithelium of normal kidney, with a significant decrease in ccRCC from our Australia patient samples. 17 The decrease in the RCC samples may help explain, in part, the negligible amount of apoptosis in RCC, and the resistance of RCC to therapies. 18, 19 No serum was available for TRAF-1 measurements from this patient cohort.
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The aim of the present study was to investigate TRAF-1 expression levels in RCC and paired normal kidney from a cohort of patients from a Malaysian hospital, to verify or otherwise the results of our work with the Australian cohort of patients. Additional investigations to our previous publication involved analysis of levels of TRAF-1 in serum from newly diagnosed, untreated ccRCC patients prior to nephrectomy, compared with age and gender-matched healthy controls to investigate any association between serum and tissue levels.
MATERIALS AND METHODS
Ethics approval for use of the human kidney tissue samples and serum was obtained from the University Malaya Medical Centre (UMMC) Ethics Committee. Written consent was obtained from all patients. The present study examined 61 cases of formalin fixed and blocked ccRCC tissue with paired normal kidney. The kidney cancer samples were taken from the periphery of the cancer, away from any necrotic core. In addition, serum was used from 15 newly diagnosed and untreated ccRCC patients prior to nephrectomy, and 15 age and gender matched healthy volunteers. Clinical data for all patients were available.
Immunohistochemistry and quantitative analysis
The present study assessed complete sections of blocks of ccRCC or normal kidney, compared with our previous study where small cores of kidney were used in multi-sample tissue microarrays. 17 Entire histology sections were used to ensure a more comprehensive comparison of TRAF-1 expression in ccRCC versus paired healthy kidney. We did this because a common criticism of tissue microarray is that the small cores of sampled cancer may not be representative of the whole tumour, 20 particularly in heterogeneous cancers such as RCC. 21 New histology sections for each specimen were stained with haematoxylin and eosin (H&E). Other sections were cut onto Superfrost Plus histology slides (Thermo Scientific, USA) for immunohistochemistry (IHC). Primary antibodies for TRAF-1 (1:1000; IHC World, US Biological, USA) were used for IHC. Positive tissue samples (human small intestine) were used for TRAF-1 to verify its activity in human tissue, and negative controls without primary antibody were prepared for each batch stain. Non-specific binding of peroxidase or antibody was blocked with 0.1% sodium azide in 0.3% hydrogen peroxide (H 2 O 2 ) in Trisbuffered saline (TBS; 10 min), followed by 5% non-fat milk powder in TBS containing 0.05% Tween-20 (Blotto; 20 min), then a 1:100 dilution of normal swine serum in 1% bovine serum albumin (BSA) in TBS (5 min). Antibodies were diluted in 1% BSA in TBS. The IHC procedure was performed using a Bond-Max automated immunostainer (Vision BioSystems, Australia) in the Histology Unit, Queensland Institute for Medical Research, Brisbane, Australia by Histology Manager, Mr Clay Winterford. The kit used for IHC was a Bond Polymer Refine Detection kit (Vision Biosystems, Cat no. DS9800). The chromogen was diaminobenzidine hydrochloride (DAB). Sections were lightly counterstained with haematoxylin and then dehydrated in a series of ethanol, cleared in xylene and mounted with glass coverslips in Depex. Thus the slides were stained in a batch in a constant environment, making comparisons in expression patterns among samples as controlled as possible. After IHC, sections were scanned in an Aperio ScanScope XT slide scanning system (Aperio Technologies, USA) at Â20 magnification. Digital images of the sections were captured using ScanScope. Three random fields of the same size were selected per RCC and paired normal kidney section (20 pairs allowed this comparison). A quantitative scoring system of overall expression, intensity and subcellular localisation of TRAF-1 was performed, using the positive pixel staining algorithms of Aperio Imagescope. 22 For quality assurance, slides were further evaluated under low power routine microscopy to provide a semi-quantitative estimate of staining intensity. Morphological evidence of apoptosis and proliferation was sought in each scanned view. 23 Serum analysis by ELISA 
Statistical analyses
Data were analysed using Student's t-test for paired groups and p < 0.05 was considered to be significant.
RESULTS
TRAF-1 had decreased expression in clear cell RCC compared with normal kidney Figure 1 shows some examples of the differences in paired ccRCC and normal kidney samples for TRAF-1 protein expression. TRAF-1 localised strongly to the proximal tubular epithelium in normal kidney (Fig. 1A,C,E) , generally accepted to be the site of origin of ccRCC. Qualitative analysis showed a lower overall cell expression intensity of TRAF-1 in ccRCC (Fig. 1B,D ,F) compared with normal kidney. The TRAF-1 expression characteristic was routinely homogeneous in the whole of the cancer tissue. Quantitative estimation of the expression intensity using Aperio ScanScope system showed that TRAF-1 expression was significantly lower in ccRCC samples ( p < 0.001) compared with paired normal kidney (Fig. 2) . In data not demonstrated, all Fuhrman grades of RCC had decreased TRAF-1, and there was no significant difference amongst the grades.
As was recorded for our previous study, 17 there was negligible apoptosis or active cell proliferation detected in any of the RCC or normal kidney sections. One novel characteristic of note in the ccRCC sections was strong TRAF-1 in inflammatory cells in and near the RCC (arrowed in Fig. 1F ).
Serum TRAF-1 was increased in RCC patient samples compared with healthy controls Serum TRAF-1 was assessed using a quantitative sandwich ELISA technique. Figure 3 demonstrates the raw data plot of RCC versus controls, with one outlier measurement for ccRCC (1168 pg/mL) removed, and one zero value for the controls removed to keep group numbers standard. TRAF-1 in serum from ccRCC patients was significantly increased over normal serum (132 AE 30 for ccRCC patients versus 54 AE 14 pg/mL for healthy controls; p ¼ 0.013). If excluded values were included, the group means were 201 AE 74 for ccRCC patients and 50 AE 13 pg/mL for controls ( p < 0.028). As far as we can ascertain, there have been no other publications of serum TRAF-1 levels in healthy people. The size of the RCC tumour may impact on the level of serum TRAF-1, but the significance of the difference should take into account patient variability in 
DISCUSSION
The current investigation verified in a Malaysian RCC patient cohort that TRAF-1 is present in the proximal tubular epithelium of normal kidney and at significantly reduced levels in ccRCC, thereby confirming our previous work in an Australian cohort of patients. 17 However, serum levels were the inverse of the tissue expression profile: serum TRAF-1 was higher in RCC patients than age and gender-matched controls. The role of TRAF proteins in RCC has not been clearly defined. One possibility for decreased TRAF-1 in RCC is that the low expression is relative to the low or negligible apoptosis levels seen in RCC histology. 17 Our previous results in cell culture indicated that TRAF-1 expression was increased in RCC cells in culture when high levels of apoptosis were induced. 16 The increased TRAF-1 in serum may reflect active secretion of the protein from the tissue as the RCC develops and, therefore, increased serum TRAF-1 may be a surrogate marker of RCC progression. RCC are predominantly solid tumours arising from the epithelial cells of the renal tubule, most commonly the proximal tubular epithelium. 3, 4 Our study from an Australian cohort at Princess Alexandra Hospital, Brisbane, used tissue microarray to investigate the expression profile of TRAF-1 in human RCC and paired normal kidney tissue. 17 One disadvantage of tissue microarray is the size of the core from the RCC paraffin block, usually from 0.6 mm to 2.0 mm in diameter. An advantage is that multiple patient samples can be analysed in the one array. However, even with selection of the cores from areas that lacked fibrosis and were comprised of tissue of the diagnosed kidney cancer subtype, and use of multiple cores from one RCC patient sample, there is still a chance that the size of the core will prevent correct interpretation of altered expression. 20 In the current study, complete sections from RCC patients were used for as representative a result as possible in this new RCC patient cohort. This method confirmed the results from the tissue microarray analysis: decreased TRAF1 expression in ccRCC compared with paired control kidney. There was also negligible apoptosis or cell proliferation seen in these sections, as had also been reported in our original analysis. 17 TRAF-1 has many roles in apoptosis, cell proliferation, differentiation, and inflammation. 24 For example, pro-apoptotic TNF signals are blocked by proteins that are induced by NF-kB, such as TRAF-1; here, the role of TRAF-1 is antiapoptotic. 25 However, specific roles may be tissue specific; for example, TRAF-1 in lung cells was required for development of allergic lung inflammation, 26 but TRAF-1 was a negative regulator of TNF signalling as demonstrated by enhanced proinflammatory TNF in TRAF-1 deficient mice. 27 From our studies and those of others, we believe TRAF-1 expression or activation does impact on levels of apoptosis in RCC, but in a pro-apoptotic manner, 16, 28 and the low levels of TRAF-1 in ccRCC may help explain why RCCs do not respond well to most therapies. 29 This analysis is very complex, because there are many molecular controls of apoptosis. Gobe and colleagues found that, in RCC with increased expression of anti-apoptotic Bcl-2 and/or Bcl-XL, levels of apoptosis were minimal, and this might have assisted with progression of the cancers and resistance to treatments. 30 However, in this same report a positive link between low expression of Bcl-2 and/or Bcl-XL in normal tissue and low expression of these proteins in RCC was seen in some patients. Enhanced resistance of RCC to chemotherapy via deficient caspase-9, or a lack of caspase-3 activation, the 'executioner' caspase with a final role in producing the structural changes of apoptosis, has been described, 31 -33 although Wu and colleagues found anthracyclines and 5-fluorouracil did induce apoptosis in RCC via cleavage of caspase-3. 34 However, overall the results indicate that regulatory molecules for apoptosis in RCC are not functioning normally or are missing. Similar principles may also apply to TRAF-1 and its presence and role in RCC apoptosis. The disparate outcome of decreased tissue versus increased serum TRAF-1 in ccRCC versus controls indicates a complex pathophysiology of TRAF-1 in RCC development and progression that needs further dissection.
TRAF-1 is also involved in the regulation of inflammatory pathways, 35 often in association with NF-kB. 36 TRAF-1, along with TRAF-2, are downstream intermediaries of the TNF receptor signal transduction pathways, regulating TNF-a activation of c-Jun N-terminal kinase and NF-kB signaling pathways. 37, 38 Additionally, expression of TRAF-1 is upregulated as a result of lymphocyte activation, and in B-cells TRAF-1 acts together with TRAF-2 to enhance CD40-mediated activation signals. 39, 40 RCC is considered an immunogenic tumour, with tumour infiltrating lymphocytes and intratumoural neutrophils. 41, 42 Although there was lower intensity of TRAF-1 in the tumour tissue, we found increased TRAF-1 expression in inflammatory cells detected in the cancers. The distribution of inflammatory cells was considered insufficient to explain the overall increased serum TRAF-1 in RCC patients, but these cells may contribute to serum TRAF-1, as it is known that cytokines, chemokines and their receptors are sometimes secreted by the tumour. 43 For example, the levels of IL6, IL-1b and TNF-a were higher in the serum of RCC patients compared to healthy controls, and RCC cells produced TNF-a. [44] [45] [46] Thus, in the current investigation, we have suggested that high serum TRAF-1 may be due to active secretion away from the RCC cells, but increased TRAF-1 in serum may also be associated with secretion from the highlyexpressing tumour-related inflammatory cells.
In conclusion, the TRAFs have disparate roles in normal tissues and multiple cancer types, and they have been proposed as targets for therapeutic intervention in some cancers. 47 TRAF-1 has diverse roles in cancer cell survival, apoptosis, and inflammation, but its role in RCC development and progression remains unclear. Specifically, from the results reported by us and others, TRAF-1 has decreased expression in RCC compared with normal kidney. We report here that TRAF-1 in serum has increased levels in RCC patients compared with healthy controls. These data require further investigation to determine why serum TRAF-1 increases in RCC patients in association with decreased TRAF-1 in RCC tissue. There is some evidence that reduced TRAF-1 may have a modulatory role on apoptosis. However, the data do indicate a potential use of TRAF-1 in diagnostic techniques using serum that may help indicate an actively growing and/or inflamed RCC.
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